Moderna's Next Test: Manufacturing a Cancer Franchise at Scale
Published on 10/08/2026 at 18:41 | Editorial boerse-global.de
Moderna has spent the past year convincing investors it can be more than a pandemic-era story. The next few weeks will test whether that pitch holds up under courtroom scrutiny, a fresh Wall Street downgrade, and the unglamorous demands of building an individualized cancer supply chain.
Melanoma Readout Set for October 24
The company's oncology ambitions hinge on data. Together with partner Merck, Moderna plans to present detailed results from the Phase 3 INTerpath-001 study in melanoma at the ESMO congress on October 24. For shareholders, the question is not whether the science sounds promising, but whether cancer therapies can become a durable revenue pillar rather than a headline generator.
The stock has already priced in a good deal of optimism. Since the Phase 3 melanoma results landed, the shares have climbed sharply, and the rally has drawn a more skeptical audience on Wall Street.
Citi Turns Bearish, Morgan Stanley Trims Its Enthusiasm
On September 30, Citigroup's Geoff Meacham downgraded Moderna from Neutral to Sell while simultaneously raising his price target from $60 to $80. The reasoning was valuation, not science: after the post-melanoma surge, the stock simply looked expensive relative to his model.
Morgan Stanley followed a day later. Analyst Terence Flynn nudged his target from $89 to $95 but kept an Equal-Weight rating. The gap between those targets and the market price remains striking. Moderna trades at 174.18 euros in European hours, up 556% year-to-date.
Should investors sell immediately? Or is it worth buying Moderna?
Index Inclusion Adds a Mechanical Tailwind
About a week ago, Nasdaq confirmed that Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before the open on Friday. The announcement alone has lifted the shares by 3.3%, as passive funds tracking the index prepare to absorb the stock. That kind of forced buying is real, but it is also mechanical — it reflects index mechanics rather than a change in the underlying business.
A Familiar Face Returns to Operations
Moderna's leadership is also shifting. Juan Andres returned as Chief Operating Officer, effective October 5, taking a newly created role, while Jerh Collins, previously Chief Technical Operations and Quality Officer, moves into retirement. A mandatory SEC filing on Monday disclosed that Andres holds direct economic ownership of 125,000 shares of common stock. That disclosure reflects an initial statement of his stake, not an open-market purchase.
The appointment signals where management sees the real work ahead. Individualized cancer therapies such as intismeran autogene require sequencing and sample processing on a per-patient basis — logistics that look nothing like the mass manufacturing model of a traditional vaccine. To secure that capability, Moderna extended its collaboration with Tempus and Merck for several years, a deal Reuters reported gave the stock meaningful support.
Delaware Court Rejects a Key Defense
Legal risk is also back on the table. According to Reuters, a federal judge in Delaware on October 1 rejected Moderna's argument that a U.S. government license shields the company from patent claims brought by Northwestern University. The ruling does not resolve whether a patent was actually infringed — only that the license defense cannot be used at this stage.
Academic mRNA Research Offers a Glimpse of What's Next
Separately, MIT researchers on September 28 unveiled an AI-driven approach that could one day allow experimental mRNA vaccines to be stored at room temperature, including nanoparticles similar to those Moderna uses. It is a university finding, not a company product announcement, but it underscores how quickly the underlying science continues to move.
For now, the market's attention stays fixed on October 24 — and on whether Moderna can turn clinical promise into operational reality before the valuation debate catches up with it.
Ad
Moderna Stock: New Analysis - 8 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
